Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | FASN | P49327 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10270142 | 0.89 | ROCK2 (0.38) | ROCK2ROCK1ALOX5HSD11B1LMNA | |
| SCHEMBL25895252 | 0.86 | — | — | |
| SCHEMBL12375166 | 0.82 | HSD11B1 (0.37) | ALOX5HSD11B1 | |
| SCHEMBL25912533 | 0.79 | BCHE (0.38) | ROCK2ROCK1ALOX5FASNLMNA | |
| SCHEMBL16727377 | 0.75 | HSD11B1 (0.34) | HSD11B1 | |
| SCHEMBL15199107 | 0.75 | HSD11B1 (0.34) | HSD11B1 | |
| SCHEMBL20622499 | 0.74 | MME (0.40) | FASN | |
| SCHEMBL10885253 | 0.74 | ROCK2 (0.38) | ROCK2ROCK1ALOX5LMNATDP1 | |
| SCHEMBL14436548 | 0.74 | ACE (0.39) | ROCK2ROCK1ALOX5LMNATDP1 | |
| SCHEMBL824158 | 0.74 | ACE (0.39) | ROCK2ROCK1ALOX5LMNATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11739074-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11739074-B2 | Ras inhibitors | KRAS, NRAS, HRAS | ROCK2 455/4885ROCK1 239/4885ALOX5 4598/4885 |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | KRAS, HRAS, MTOR | ROCK2 660/4885ROCK1 567/4885ALOX5 3385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.